CU22774A3 - Nueva variante cristalina del cdch, procedimiento para su producción y preparados farmacéuticos que la contienen - Google Patents

Nueva variante cristalina del cdch, procedimiento para su producción y preparados farmacéuticos que la contienen

Info

Publication number
CU22774A3
CU22774A3 CU1996111A CU1996111A CU22774A3 CU 22774 A3 CU22774 A3 CU 22774A3 CU 1996111 A CU1996111 A CU 1996111A CU 1996111 A CU1996111 A CU 1996111A CU 22774 A3 CU22774 A3 CU 22774A3
Authority
CU
Cuba
Prior art keywords
cdch
production
pharmaceutical preparations
variante
procedure
Prior art date
Application number
CU1996111A
Other languages
English (en)
Spanish (es)
Inventor
Alfons Grunenberg
Patrick Bosche
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7779831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU22774(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of CU22774A3 publication Critical patent/CU22774A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CU1996111A 1995-12-12 1996-11-27 Nueva variante cristalina del cdch, procedimiento para su producción y preparados farmacéuticos que la contienen CU22774A3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19546249A DE19546249A1 (de) 1995-12-12 1995-12-12 Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
CU22774A3 true CU22774A3 (es) 2002-07-24

Family

ID=7779831

Family Applications (1)

Application Number Title Priority Date Filing Date
CU1996111A CU22774A3 (es) 1995-12-12 1996-11-27 Nueva variante cristalina del cdch, procedimiento para su producción y preparados farmacéuticos que la contienen

Country Status (42)

Country Link
US (1) US5849752A (enEXAMPLES)
EP (1) EP0780390B1 (enEXAMPLES)
JP (1) JP4104687B2 (enEXAMPLES)
KR (1) KR100525146B1 (enEXAMPLES)
CN (1) CN1061348C (enEXAMPLES)
AR (1) AR005009A1 (enEXAMPLES)
AT (1) ATE221531T1 (enEXAMPLES)
AU (1) AU708006B2 (enEXAMPLES)
BG (1) BG62258B1 (enEXAMPLES)
BR (1) BR9605968A (enEXAMPLES)
CA (1) CA2192418C (enEXAMPLES)
CO (1) CO4480105A1 (enEXAMPLES)
CU (1) CU22774A3 (enEXAMPLES)
CZ (1) CZ288657B6 (enEXAMPLES)
DE (2) DE19546249A1 (enEXAMPLES)
DK (1) DK0780390T3 (enEXAMPLES)
EE (1) EE03474B1 (enEXAMPLES)
ES (1) ES2179910T3 (enEXAMPLES)
HR (1) HRP960558B1 (enEXAMPLES)
HU (1) HU226521B1 (enEXAMPLES)
ID (1) ID22625A (enEXAMPLES)
IL (1) IL119795A (enEXAMPLES)
IN (1) IN185805B (enEXAMPLES)
MA (1) MA24342A1 (enEXAMPLES)
MY (1) MY117492A (enEXAMPLES)
NL (1) NL300109I1 (enEXAMPLES)
NO (1) NO306725B1 (enEXAMPLES)
NZ (1) NZ299905A (enEXAMPLES)
PL (1) PL184885B1 (enEXAMPLES)
PT (1) PT780390E (enEXAMPLES)
RO (1) RO119782B1 (enEXAMPLES)
RU (1) RU2162468C2 (enEXAMPLES)
SA (1) SA96170492B1 (enEXAMPLES)
SG (1) SG47201A1 (enEXAMPLES)
SI (1) SI0780390T1 (enEXAMPLES)
SK (1) SK282805B6 (enEXAMPLES)
SV (1) SV1996000109A (enEXAMPLES)
TR (1) TR199600970A2 (enEXAMPLES)
TW (1) TW411340B (enEXAMPLES)
UA (1) UA35638C2 (enEXAMPLES)
YU (1) YU49485B (enEXAMPLES)
ZA (1) ZA9610405B (enEXAMPLES)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU731693B2 (en) * 1997-09-25 2001-04-05 Bayer Intellectual Property Gmbh Drug formulation having controlled release of active compound
DE19751948A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
DE59910858D1 (de) * 1998-11-10 2004-11-18 Bayer Healthcare Ag Pharmazeutische zubereitung von moxifloxacin
DE19854357A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Semi-Hydrochlorid von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo/4.3.0/ -nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854356A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854355A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19908449A1 (de) 1999-02-26 2000-08-31 Bayer Ag Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure
WO2004039804A1 (en) * 2002-10-31 2004-05-13 Ranbaxy Laboratories Limited Amorphous moxifloxacin hydrochloride
ES2332367T5 (es) * 2003-04-09 2013-12-17 Dr. Reddy's Laboratories Ltd. Forma cristalina III de clorhidrato de moxifloxacina anhidro y su procedimiento de preparación
WO2005012285A1 (en) * 2003-08-05 2005-02-10 Matrix Laboratories Ltd An improved process for the preparation of moxifloxacin hydrochloride
ITMI20032259A1 (it) 2003-11-20 2005-05-21 Chemi Spa Nuovo polimorfo dell'acido 1-ciclopropil-7-(s,s-2,8-diazabciclo-4.3.0-non-8-il)-6-fluoro-1,4-diidro-8-metossi-4-oxo-chinolin carbossilico cloridrato e metodi per la sua preparazione
DE602004018370D1 (de) * 2003-11-20 2009-01-22 Chemi Spa Polymorphe von 1-cyclopropyl-7-(äs,sü - 2,8-diazadicyclo ä4.3.0ü non-8-yl) -6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäurehydrochlorid und verfahren zu deren herstellung
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
DE102004015981A1 (de) * 2004-04-01 2005-10-20 Bayer Healthcare Ag Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE102004063347A1 (de) * 2004-12-23 2006-07-13 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
GB0612422D0 (en) * 2006-06-23 2006-08-02 Generics Uk Ltd Novel hydrate form
WO2008000418A2 (en) 2006-06-27 2008-01-03 Sandoz Ag New method for salt preparation
ES2303768B1 (es) * 2006-09-08 2009-06-05 Quimica Sintetica, S.A. Nueva forma cristalina de moxifloxacino clorhidrato.
IN2014MN02582A (enEXAMPLES) * 2006-11-13 2015-09-11 Cipla Ltd
EP1992626A1 (en) * 2007-05-10 2008-11-19 Sandoz AG Process for the preparation of moxifloxacin hydrochloride
EP2083010A1 (en) * 2008-01-08 2009-07-29 Chemo Ibérica, S.A. Polymorphic Forms of Moxifloxacin hydrochloride and processes for preparation thereof
EP2154137A1 (en) 2008-08-04 2010-02-17 Chemo Ibérica, S.A. Crystalline form of moxifloxacin base
EP2349220B1 (en) * 2008-10-09 2012-07-25 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Using of organic solvents in wet granulation of moxifloxacin
WO2010052726A1 (en) * 2008-11-06 2010-05-14 Hetero Research Foundation Novel polymorph of moxifloxacin hydrochloride
EP2837376A3 (de) 2008-12-08 2015-03-25 ratiopharm GmbH Kompaktiertes Moxifloxacin
BRPI1010981A2 (pt) 2009-05-15 2018-12-04 Redx Pharma Ltd "derivados de fármaco redox"
WO2011121596A2 (en) * 2010-04-01 2011-10-06 Neuland Laboratories Ltd. Crystal modification of moxifloxacin hydrochloride
BRPI1106900A2 (pt) 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
FR2992218B1 (fr) 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
CN102924449B (zh) * 2012-10-30 2015-08-12 重庆福安药业集团庆余堂制药有限公司 盐酸莫西沙星h晶型及其制备方法和药物组合物
CA2893534A1 (en) 2012-12-04 2014-06-12 Mankind Research Centre An improved process for the preparation of moxifloxacin hydrochloride
RU2561037C2 (ru) * 2013-02-07 2015-08-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Антибактериальная фармацевтическая композиция и способ ее получения
AU2014239965A1 (en) 2013-03-15 2015-09-24 Melinta Subsidiary Corp. Methods of treating infections in overweight and obese patients using antibiotics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601567A1 (de) * 1986-01-21 1987-07-23 Bayer Ag 7-(azabicycloalkyl)-chinoloncarbonsaeure- und -naphthyridon-carbonsaeure-derivate
CN1019114B (zh) * 1986-03-31 1992-11-18 三共株式会社 喹啉-3-羟酸衍生物的制备方法
AU609974B2 (en) * 1988-05-18 1991-05-09 Warner-Lambert Company Improved process for the preparation of 5-amino-7- (substituted amino)-quinoline-3-carboxylic acids
DE3910663A1 (de) * 1989-04-03 1990-10-04 Bayer Ag 5-alkylchinoloncarbonsaeuren
RO108347B1 (ro) * 1989-10-30 1994-04-28 Bellon Labor Sa Roger DERIVATI DE BENZO-(b)-NAFTIRIDIN-1,8 SI PROCEDEU DE PREPARARE A ACESTORA
TW209865B (enEXAMPLES) 1992-01-10 1993-07-21 Bayer Ag
KR100228572B1 (ko) * 1992-01-31 1999-11-01 이병언 퀴놀론카르복실산 유도체 수화물 결정
DE4234078A1 (de) * 1992-10-09 1994-04-14 Bayer Ag Chinoloncarbonsäuren
CA2112165C (en) * 1992-12-25 2003-04-08 Makoto Takemura Bicyclic amine derivatives
ZA946853B (en) * 1993-09-10 1995-04-24 Daiichi Seiyaku Co Crystals of antimicrobial compound.
EP0676199B1 (en) * 1994-04-07 1998-09-02 Pfizer Inc. Use of trovafloxacin or derivatives thereof for the manufacture of a medicament for the treatment of H. pylori infections

Also Published As

Publication number Publication date
BG101043A (en) 1998-04-30
NZ299905A (en) 1998-09-24
IL119795A (en) 1998-12-27
HU9603428D0 (en) 1997-01-28
IN185805B (enEXAMPLES) 2001-05-05
RU2162468C2 (ru) 2001-01-27
NO306725B1 (no) 1999-12-13
EE9600201A (et) 1997-06-16
CA2192418A1 (en) 1997-06-13
ES2179910T3 (es) 2003-02-01
EP0780390A1 (de) 1997-06-25
CO4480105A1 (es) 1997-07-09
AU708006B2 (en) 1999-07-29
ATE221531T1 (de) 2002-08-15
NO965298D0 (no) 1996-12-11
PL317415A1 (en) 1997-06-23
EE03474B1 (et) 2001-08-15
JPH09169757A (ja) 1997-06-30
BR9605968A (pt) 1998-08-18
IL119795A0 (en) 1997-03-18
SG47201A1 (en) 1998-03-20
SA96170492B1 (ar) 2006-05-23
PT780390E (pt) 2002-11-29
ZA9610405B (en) 1997-06-23
MY117492A (en) 2004-07-31
TW411340B (en) 2000-11-11
MA24342A1 (fr) 1998-07-01
HRP960558B1 (en) 2002-04-30
YU49485B (sh) 2006-08-17
MX9606325A (es) 1997-10-31
SI0780390T1 (en) 2002-10-31
RO119782B1 (ro) 2005-03-30
AR005009A1 (es) 1999-04-07
BG62258B1 (bg) 1999-06-30
HU226521B1 (en) 2009-03-30
CN1061348C (zh) 2001-01-31
PL184885B1 (pl) 2003-01-31
SK282805B6 (sk) 2002-12-03
KR100525146B1 (ko) 2006-01-27
ID22625A (id) 1999-12-02
YU65096A (sh) 1998-12-23
EP0780390B1 (de) 2002-07-31
CA2192418C (en) 2001-06-12
JP4104687B2 (ja) 2008-06-18
NO965298L (no) 1997-06-13
DK0780390T3 (da) 2002-11-11
KR970042550A (ko) 1997-07-24
HUP9603428A2 (en) 1997-08-28
CZ364696A3 (en) 1997-07-16
DE19546249A1 (de) 1997-06-19
AU7421696A (en) 1997-06-19
NL300109I1 (nl) 2003-02-03
SV1996000109A (es) 1997-10-23
HRP960558A2 (en) 1998-02-28
CZ288657B6 (cs) 2001-08-15
CN1160052A (zh) 1997-09-24
HUP9603428A3 (en) 1997-10-28
DE59609501D1 (de) 2002-09-05
US5849752A (en) 1998-12-15
TR199600970A2 (tr) 1997-06-21
UA35638C2 (uk) 2001-04-16
SK159196A3 (en) 1997-10-08

Similar Documents

Publication Publication Date Title
CU22774A3 (es) Nueva variante cristalina del cdch, procedimiento para su producción y preparados farmacéuticos que la contienen
GB2303629B (en) Hydroxamic acids and their use as metalloproteinase inhibitors
UA29450C2 (uk) Похідні гідроксамової кислоти, спосіб їх одержання, спосіб впливу на хвороби та фармацевтична або ветеринарна композиція, що їх містить
ECSP055738A (es) PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL
DE69807741D1 (de) Neuartige verbindungen
IL114449A0 (en) Multiple unit tableted dosage form
AR030541A1 (es) Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica
HUT51269A (en) Process for producing benzimidazole derivatives and pharmaceutical compositions comprising same
SI1546127T1 (sl) Novi pirimidinamidni derivati in njihova uporaba
IT1265101B1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
HUT54988A (en) Process for producing substituted n-(quinolin-2-ylmethoxy)-benzylsulfonylureas and pharmaceutical compositions comprising such compounds
NO172537C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-desmetyl-4-fluor-mevalonsyrederivater
ES2124861T3 (es) Derivados de aminoacidos y su utilizacion como inhibidores de la encefalinasa.
AU2002224847A1 (en) N-alkylated gaba compounds, processes for their preparation and their use as medicaments
DE59010302D1 (de) R-(-)-1-(5-Hydroxyhexyl)-3-methyl-7-propylxanthin, Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel
ECSP961966A (es) Nueva variante cristalina del cdch. procedimiento para su produccion y preparados farmaceuticos que la contienen
DE69804766D1 (de) Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
EP0316639A3 (en) Azelastin embonate, process for its preparation and pharmaceutical compositions containing azelastin embonate as the active ingredient
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
ZA824649B (en) New optically active dipeptides, process for their preparation and pharmaceutical products containing these compounds
DE60237994D1 (de) 3.beta.,28-diacetoxy-18-oxo-19,20,21,29,30-pentanorlupan-22-säure solvate, verfahren zu ihrer herstellung und pharmazeutische präparate daraus
AU2506188A (en) Azelastine embonate, processes for its preparation and pharmaceutical formulations which contain azelastine embonate as active substance
IL160160A0 (en) SUBSTITUTED 5,6,6a, 11b-TETRAHYDRO-7-OXA-5-AZA-BENZO[c]FLUORENE-6-CARBOXYLIC ACID DERIVATIVES SERVING AS NMDA ANTAGONISTS
IT1254471B (it) Derivati ammidici della (r)-glicerofosforil-(s)-serina o del suo diacil derivato, un processo per la loro preparazione e relative composizioni farmaceutiche per il potenziamento dei processi di apprendimento
HU9201315D0 (en) Process for the production of medical preparations containing 4-/n,n-dibenzyl-amino/-butyric acid or butyric amid as active agent, or their medically useful salts

Legal Events

Date Code Title Description
MK Ceased due to expiration of term